Box-Behnken Optimized Olmesartan Sublingual Tablets: A Quality by Design Study

Abstract

Background: Heart failure is a progressive cardiovascular condition associated with high morbidity and mortality. Although Olmesartan, an angiotensin II receptor antagonist, is effective in managing heart failure, its conventional oral route is limited by poor solubility and variable bioavailability.

Purpose: This study aimed to develop a fast-dissolving sublingual tablet of Olmesartan using a Quality by Design (QbD) framework, integrating Box–Behnken Design (BBD) optimization with ex vivo permeation analysis to enhance systemic absorption.

Methods: Three critical formulation variables—Sodium Starch Glycolate (SSG), Crospovidone (CP), and Croscarmellose Sodium (CCS)—were evaluated for their effect on disintegration time (DT) and cumulative drug release (CDR).

Result: The optimized formulation (OOSF-18), containing 9 mg SSG, 9 mg CP, and 6.44 mg CCS, exhibited a DT of 33.33 s and 92.33% CDR, with strong model predictability (adjusted R² = 0.9961 for DT and 0.9806 for CDR). Ex vivo permeation through porcine mucosa reached 89.76% within 10 min, indicating rapid transmucosal delivery potential. Stability studies confirmed formulation robustness over six months.

Conclusion: This combined QbD permeation strategy demonstrates a novel and efficient approach for improving Olmesartan’s bioavailability and offers translational potential for rapid-acting sublingual antihypertensive therapy.

  • Page Number : 93-104
  • Published Date : 2025-12-24
  • Keywords
    Quality by design, Box–Behnken design, Sublingual tablet, Olmesartan, Ex vivo permeation
  • DOI Number
    10.15415/jptrm.2025.131007
  • Authors
    Deepak Joshi, Pawandeep Shukla and Naveen Kumar Choudhary

References

  • Al-Madhagi, W., Abdulbari Albarakani, A., Khaled Alhag, A., Ahmed Saeed, Z., Mansour Noman, N., & Mohamed, K. (2017). Formulation and evaluation of new glimepiride sublingual tablets. Journal of pharmaceutics, 2017(1), 3690473. https://doi.org/10.1155/2017/3690473
  • Ashok Mahajan, Parmar, J., Patel, P., Koradiya, S., & Mehta, F. (2022). Formulation, evaluation and optimization of sublingual tablet of clonidine HCl. International Journal of Life Science and Pharma Research.
  • Charankumar, K., Bagasariya, D., Jain, N., Famta, P., Shah, S., Vambhurkar, G., Fernandes, V., Khatri, D. K., Singh, S. B., & Srivastava, S. (2023). Quality by design (QbD)-abetted development of pioglitazone incorporated liposomes-loaded hyaluronic acid-based in situ hydrogel for the management of melanoma. Journal of Drug Delivery Science and Technology, 84, Article 104453. https://doi.org/10.1016/j.jddst.2023.104453
  • Chordiya, M., Gangurde, H., & Sancheti, V. (2019). Quality by design: A roadmap for quality pharmaceutical products. Journal of Reports in Pharmaceutical Sciences, 8(2), 289-294. https://doi.org/10.4103/jrptps.JRPTPS_2_18
  • Choudhary, N. K., & Joshi, D. (2025). Formulation and optimization of olmesartan sublingual tablets using Box–Behnken design: A QbD and ex vivo study. Journal of Pharmaceutical Innovation, 20(6), 223. https://doi.org/10.1007/s12247-025-10160-y
  • Dhawan, S., & Nanda, S. (2023). Implementation of quality by design (QbD) concept for the development of emulsion-based nanotailored gel for improved antiphotoageing potential of silymarin. Journal of Drug Delivery Science and Technology, 81, Article 104201. https://doi.org/10.1016/j.jddst.2023.104201
  • Dubey, I., Joshi, D., Walvekar, A., Pandey, P. K., & Singh Chouhan, P. (2025). QbD-based optimization of fast dissolving sublingual tablets of valsartan. Journal of Pharmaceutical Innovation, 20(2), 75. https://doi.org/10.1007/s12247-025-09983-6
  • Hasnain, M. S., Ahmed, S. A., Khatoon, A., Afzal, M., Ansari, M. T., Khatoon, S., Tabish, M., Al-Marshad, F. M., & Nayak, A. K. (2021). Pharmaceutical product development: A quality by design (QbD) approach. In Advances and Challenges in Pharmaceutical Technology: Materials, Process Development and Drug Delivery Strategies (pp. 131–146). Elsevier. https://doi.org/10.1016/B978-0-12-820043-8.00017-7
  • Joshi, D., & Choudhary, N. K. (2023). Enhancing sublingual tablet quality through QbD: Current trends and insights. Precision Nanomedicine, 6(3), 1099–1108. https://doi.org/10.33218/001c.88223
  • Kadry, H., Omar, A., Sherbiny, F., & Zaky, A. (2016). Design and optimization of captopril sublingual tablets: Enhancement of pharmacokinetic parameters in human. Al-Azhar Journal of Pharmaceutical Sciences, 53(1), 90–107. https://doi.org/10.21608/ajps.2016.6889
  • Kayrak-Talay, D., Dale, S., Wassgren, C., & Litster, J. (2013). Quality by design for wet granulation in pharmaceutical processing: Assessing models for a priori design and scaling. Powder Technology, 240, 7–18. https://doi.org/10.1016/j.powtec.2012.07.013
  • Mayet-Cruz, L., Rodríguez, J. M., & Jung-Cook, H. (2021). Development of a dissolution test for melatonin sublingual tablets using a factorial experimental design. Farmacia, 69(1), 169-173. https://doi.org/10.31925/farmacia.2021.1.23
  • Mishra, V., Thakur, S., Patil, A., & Shukla, A. (2018). Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opinion on Drug Delivery, 15(8), 737–758. https://doi.org/10.1080/17425247.2018.1504768
  • Pawar, A., Londhe, V. Y., & Bhadale, R. S. (2022). Formulation and characterization of sublingual tablets of iloperidone prepared by microenvironmental pH regulated approach. Journal of Pharmaceutical Innovation, 17(1), 104-110. https://doi.org/10.1007/s12247-020-09502-9
  • Pramod, K., Tahir, M., Charoo, N., Ansari, S., & Ali, J. (2016). Pharmaceutical product development: A quality by design approach. International Journal of Pharmaceutical Investigation, 6(3), 129–138. https://doi.org/10.4103/2230-973X.187350
  • Sangshetti, J. N., Deshpande, M., Zaheer, Z., Shinde, D. B., & Arote, R. (2017). Quality by design approach: Regulatory need. Arabian Journal of Chemistry, 10, S3412–S3425. https://doi.org/10.1016/j.arabjc.2014.01.025
  • Simão, J., Chaudhary, S. A., & Ribeiro, A. J. (2023). Implementation of quality by design (QbD) for development of bilayer tablets. European Journal of Pharmaceutical Sciences, 184, Article 106412. https://doi.org/10.1016/j.ejps.2023.106412
  • Singh, M. K., Mazumder, R., Padhi, S., & Singh, D. K. (2022). Formulation development and optimization of bioenhanced sublingual tablets of rizatriptan benzoate to combat migraine. Indian Journal of Pharmaceutical Education and Research, 56(2), s200-s215. https://doi.org/10.5530/ijper.56.2s.91
  • Verma, P., & Yadav, K. S. (2023). Quality by design (QbD)-enabled and Box–Behnken design-assisted approach for formulation of tranexamic acid loaded stratum corneum lipid liposomes. Journal of Drug Delivery Science and Technology, 86, Article 104571. https://doi.org/10.1016/j.jddst.2023.104571
  • Won, D. H., Park, H., Ha, E. S., Kim, H. H., Jang, S. W., & Kim, M. S. (2021). Optimization of bilayer tablet manufacturing process for fixed-dose combination of sustained-release high-dose drug and immediate-release low-dose drug based on quality by design (QbD). International Journal of Pharmaceutics, 605, Article 120838. https://doi.org/10.1016/j.ijpharm.2021.120838
  • Yu, L. X., Amidon, G., Khan, M. A., Hoag, S. W., Polli, J., Raju, G. K., & Woodcock, J. (2014). Understanding pharmaceutical quality by design. The AAPS Journal, 16(4), 771–783. https://doi.org/10.1208/S12248-014-9598-3
  • Zagalo, D. M., Silva, B. M. A., Silva, C., Simões, S., & Sousa, J. J. (2022). A quality by design (QbD) approach in pharmaceutical development of lipid-based nanosystems: A systematic review. Journal of Drug Delivery Science and Technology, 70, Article 103207. https://doi.org/10.1016/j.jddst.2022.103207